STOCK TITAN

Outlook Therapeutics Inc - OTLK STOCK NEWS

Welcome to our dedicated news page for Outlook Therapeutics (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Outlook Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Outlook Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.87%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
management
Outlook Therapeutics Inc

Nasdaq:OTLK

OTLK Rankings

OTLK Stock Data

187.78M
6.07M
36.82%
23.53%
6.14%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Iselin

About OTLK

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t